SOLIGENIX, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
SOLIGENIX, INC. (SNGX) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 1.81 million shares for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2015-11-12
- SOLIGENIX, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2015-09-30 was 1.81M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month |
|---|---|
| 2015-09-30 | 1.81M shares 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |